JP2002514405A5 - - Google Patents

Download PDF

Info

Publication number
JP2002514405A5
JP2002514405A5 JP2000548372A JP2000548372A JP2002514405A5 JP 2002514405 A5 JP2002514405 A5 JP 2002514405A5 JP 2000548372 A JP2000548372 A JP 2000548372A JP 2000548372 A JP2000548372 A JP 2000548372A JP 2002514405 A5 JP2002514405 A5 JP 2002514405A5
Authority
JP
Japan
Prior art keywords
antibody
domain
fibronectin
affinity
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000548372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002514405A (ja
Filing date
Publication date
Priority claimed from US09/300,425 external-priority patent/US20030045681A1/en
Application filed filed Critical
Priority claimed from PCT/EP1999/003210 external-priority patent/WO1999058570A2/en
Publication of JP2002514405A publication Critical patent/JP2002514405A/ja
Publication of JP2002514405A5 publication Critical patent/JP2002514405A5/ja
Pending legal-status Critical Current

Links

JP2000548372A 1998-05-11 1999-05-11 フィブロネクチンのed−bドメインに対する抗体、それを含有する抱合体、および、腫瘍および血管新生関連の疾病の診断および治療をするためのそれの用途 Pending JP2002514405A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7533898A 1998-05-11 1998-05-11
US09/075,338 1998-05-11
US09/300,425 1999-04-28
US09/300,425 US20030045681A1 (en) 1998-05-11 1999-04-28 Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
PCT/EP1999/003210 WO1999058570A2 (en) 1998-05-11 1999-05-11 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009191668A Division JP2009280607A (ja) 1998-05-11 2009-08-21 フィブロネクチンのed−bドメインに対する抗体、それを含有する抱合体、および、腫瘍および血管新生関連の疾病の診断および治療をするためのそれの用途

Publications (2)

Publication Number Publication Date
JP2002514405A JP2002514405A (ja) 2002-05-21
JP2002514405A5 true JP2002514405A5 (cg-RX-API-DMAC10.html) 2006-01-05

Family

ID=26756726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000548372A Pending JP2002514405A (ja) 1998-05-11 1999-05-11 フィブロネクチンのed−bドメインに対する抗体、それを含有する抱合体、および、腫瘍および血管新生関連の疾病の診断および治療をするためのそれの用途

Country Status (24)

Country Link
US (1) US20070189963A1 (cg-RX-API-DMAC10.html)
EP (1) EP1084145B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002514405A (cg-RX-API-DMAC10.html)
CN (1) CN1250571C (cg-RX-API-DMAC10.html)
AT (1) ATE301676T1 (cg-RX-API-DMAC10.html)
AU (1) AU759207B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI9910394B8 (cg-RX-API-DMAC10.html)
CA (1) CA2333833C (cg-RX-API-DMAC10.html)
CZ (1) CZ300495B6 (cg-RX-API-DMAC10.html)
DE (1) DE69926630T2 (cg-RX-API-DMAC10.html)
DK (1) DK1084145T3 (cg-RX-API-DMAC10.html)
EA (1) EA005685B1 (cg-RX-API-DMAC10.html)
EE (1) EE05435B1 (cg-RX-API-DMAC10.html)
ES (1) ES2247802T3 (cg-RX-API-DMAC10.html)
HU (1) HU225675B1 (cg-RX-API-DMAC10.html)
IL (1) IL139452A0 (cg-RX-API-DMAC10.html)
IS (1) IS2522B (cg-RX-API-DMAC10.html)
NO (1) NO327732B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ508600A (cg-RX-API-DMAC10.html)
PL (1) PL199353B1 (cg-RX-API-DMAC10.html)
SK (1) SK286822B6 (cg-RX-API-DMAC10.html)
TR (1) TR200003317T2 (cg-RX-API-DMAC10.html)
TW (1) TWI259837B (cg-RX-API-DMAC10.html)
WO (1) WO1999058570A2 (cg-RX-API-DMAC10.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
NZ511219A (en) * 1999-01-05 2003-05-30 Univ Southern Australia Novel agents and methods for treatment and diagnosis of ocular disorders
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US20020197700A1 (en) * 2000-09-07 2002-12-26 Schering Ag Receptor of the EDb-fibronectin domains
DE10045803A1 (de) * 2000-09-07 2002-04-11 Schering Ag Rezeptor der EDb Fibronektin-Domäne
US20030100010A1 (en) * 2001-11-23 2003-05-29 George Jackowski Fibrinogen biopolymer Marker predictive of type II diabetes
WO2003047633A2 (en) * 2001-12-04 2003-06-12 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
PL369371A1 (en) * 2002-01-03 2005-04-18 Schering Aktiengesellschaft New methods for diagnosis and treatment of tumours
DK1461360T3 (da) * 2002-01-03 2010-11-15 Bayer Schering Pharma Ag Konjugater omfattende et antistofspecifik for ED-8-domæner af fibronectin og deres anvendelse til påvisning og behandling af tumorer
ES2337566T3 (es) * 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
DE60335383D1 (de) 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1957531B1 (en) * 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
DE502005009389D1 (de) * 2005-11-09 2010-05-20 Morphosys Ag Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP2085095B1 (en) 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
JP2009244154A (ja) 2008-03-31 2009-10-22 Nationa Hospital Organization 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
US20110306065A1 (en) * 2008-11-12 2011-12-15 The Trustees Of The University Of Pennsylvania Use of an antibody and a rare-earth based crystal
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
DK2721152T3 (da) 2011-06-15 2019-07-01 Navigo Proteins Gmbh Dimere bindingsproteiner baseret på modificerede ubiquitiner
US9549981B2 (en) 2011-07-19 2017-01-24 Philogen S.P.A. Sequential antibody therapy
RU2481839C2 (ru) * 2011-08-16 2013-05-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет Министерства здравоохранения и социального развития" Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий
EP2861616A1 (en) 2012-06-13 2015-04-22 Scil Proteins GmbH Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
EP3029065B1 (en) * 2013-06-06 2020-05-27 Hefei Lifeon Pharmaceutical Co. Ltd. Human antibody against ed-b domain of fibronectin and uses thereof
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
DK3322721T3 (da) 2015-07-16 2022-03-14 Navigo Proteins Gmbh Nye immunglobulin-bindende proteiner og deres anvendelse i affinitetsoprensning
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
EP3378947B1 (en) * 2015-11-16 2024-01-24 Hefei Lifeon Pharmaceutical Co. Ltd. Use of ed-b protein in diagnosis of tissue hyperplasia
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US11230576B2 (en) 2016-08-11 2022-01-25 Navigo Proteins Gmbh Alkaline stable immunoglobulin-binding proteins
IL310865A (en) 2016-10-17 2024-04-01 Pfizer Antibodies against EDB and antibody-drug conjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
EP3689903A4 (en) * 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. BINDING OF PROTEIN TO FIBRONECTIN B DOMAIN
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
KR20210104106A (ko) 2018-12-18 2021-08-24 나피고 프로타인스 게엠베하 암 진단 및 치료를 위한 신규 folr1 특이적 결합 단백질
JP2024524891A (ja) 2021-06-23 2024-07-09 サイチューン ファーマ インターロイキン-15に基づく免疫サイトカイン
JP2024526080A (ja) 2021-06-23 2024-07-17 サイチューン ファーマ インターロイキン15多様体
US20250073239A1 (en) 2022-01-04 2025-03-06 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
WO2024028258A1 (en) 2022-08-01 2024-02-08 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
AU2023332212A1 (en) 2022-09-01 2025-04-10 Philogen S.P.A. Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer
CA3266566A1 (en) 2022-09-06 2024-03-14 Philochem Ag MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
EP4780495A1 (en) 2023-09-19 2026-07-29 Philochem AG Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods

Similar Documents

Publication Publication Date Title
CA2333833A1 (en) Specific binding molecules for scintigraphy,conjugates containing them and therapeutic method for treatment of angiogenesis
JP7171877B2 (ja) Vegfを阻害する安定かつ可溶性の抗体
JP6437922B2 (ja) Bcma抗原結合タンパク質
AU2017202150B2 (en) Antibody drug conjugates and corresponding antibodies
RU2588467C2 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP7037884B2 (ja) Hpv及びhpv関連疾患に対する新規のワクチン
JP6251678B2 (ja) Cd27l抗原結合タンパク質
US20240189439A1 (en) Antibodies to pmel17 and conjugates thereof
JP2003524018A5 (cg-RX-API-DMAC10.html)
CN112996540B (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
TW202229346A (zh) 用於治療癌症之人化抗liv1抗體
TWI864487B (zh) 抗il-17/vegf雙功能融合蛋白及其用途
HK40112252A (en) Antibodies to pmel17 and conjugates thereof
WO2026046241A1 (zh) 一种包含抗dll3抗体药物偶联物的药物组合物
TW202527984A (zh) 5t4抗體藥物結合物及其使用之方法
JP2024544058A (ja) 抗葉酸受容体コンジュゲートがん治療法
AU2013202998B2 (en) Stable and soluble antibodies inhibiting vegf
AU2017204337A1 (en) Stable and soluble antibodies inhibiting vegf